Liquidia Technologies is trading 11.1% down now at $26.90 after a Delaware federal court found YUTREPIA infringed two valid claims of United Therapeutics’ patent covering treatment of pulmonary hypertension associated with interstitial lung disease. - The ruling followed a steep September 30 selloff; the court invalidated the other asserted claims. - The parties must propose remedies within one week. - Liquidia plans to appeal and seek PH-ILD indication removal from YUTREPIA’s label; potential remedies remain uncertain.